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Alzheimer’s disease (AD) is strongly influenced by
genetic factors as evidenced by numerous family and
twin studies. Over the past two decades, others and we
have co-discovered three early-onset familial AD genes,
APP, PSEN1, and PSEN2, which can carry any of >200
fully penetrant mutations characterized by mendelian
inheritance. For late-onset AD, the most prevalent and
highest impact risk factor is the epsilon 4 variant of
APOE, which increases risk by 3.7-fold in the heterozy-
gous state and >10-fold when two copies are inherited.
As part of our Alzheimer’s Genome Project funded by
the Cure Alzheimer’s Fund and the NIMH, we have
been identifying novel AD candidate genes. In Bertram
et al. (2008), we reported genome-wide association of
AD with several loci including the spinocerebellar ataxia 1
gene, ATXN1, and the SIGLEC3 gene, CD33. Functional
studies of the ATXN1 gene carried out both in vitro and in
vivo in ATXN1 knockout mice show that ATXN1 can
regulate Ab levels via modulation of b-secretase. CD33 is
just one of several genes (TREM2, CR1, etc) involved in
the innate immune system of the brain that have been
associated with AD risk. In addition, we discovered asso-
ciation of AD with ADAM10, which encodes the major
a-secretase in the brain. Re-sequencing of this gene in the
best associated AD families led to two rare mutations that
tightly co-segregated with AD in seven (of 1000) AD
families screened, all with average age of onset ~70 years.
We have shown both mutations to impair ADAM10 non-
amyloidogenic cleavage of APP in vitro and in transgenic
mice, including double trangenics with AD (tg2576) mice.
Thus, these are the first rare, highly penetrant mutations
reported for late-onset AD. We have also carried out gen-
ome-wide association studies on >800 well-characterized
late-onset AD families (NIMH and NIA-LOAD samples)
using Affymetrix genotyping arrays containing either one
million (6.0) or 20,000 coding SNPs. More recently, we
have performed whole genome sequencing (Illumina,
Hiseq) on over 1500 samples from AD families/sibships.
The elucidation of the genes and functional variants
influencing risk for AD should continue to enhance
our understanding of AD etiology and pathogenesis.
Ultimately, these genes will be used to predict risk for AD
and guide novel the development of therapies for the effec-
tive treatment and prevention of this terrible disease.
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